These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 29428518)

  • 1. EFEMP2 Mediates GALNT14-Dependent Breast Cancer Cell Invasion.
    Zuo T; Shan J; Liu Y; Xie R; Yu X; Wu C
    Transl Oncol; 2018 Apr; 11(2):346-352. PubMed ID: 29428518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GALNT14 Involves the Regulation of Multidrug Resistance in Breast Cancer Cells.
    Shan J; Liu Y; Wang Y; Li Y; Yu X; Wu C
    Transl Oncol; 2018 Jun; 11(3):786-793. PubMed ID: 29702465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GALNT14 mediates tumor invasion and migration in breast cancer cell MCF-7.
    Huanna T; Tao Z; Xiangfei W; Longfei A; Yuanyuan X; Jianhua W; Cuifang Z; Manjing J; Wenjing C; Shaochuan Q; Feifei X; Naikang L; Jinchao Z; Chen W
    Mol Carcinog; 2015 Oct; 54(10):1159-71. PubMed ID: 24962947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-125a regulates ovarian cancer proliferation and invasion by repressing GALNT14 expression.
    Yang J; Li G; Zhang K
    Biomed Pharmacother; 2016 May; 80():381-387. PubMed ID: 27133078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osterix Decreases the Chemosensitivity of Breast Cancer Cells by Upregulating GALNT14.
    Wu J; Chen X; Bao Q; Duan R; Jin Y; Shui Y; Yao B; Lu X; Wang Y; Cui H; Li L; Yuan H; Ma C
    Cell Physiol Biochem; 2017; 44(3):998-1010. PubMed ID: 29227978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EFEMP2 Inhibits Breast Cancer Invasion And Metastasis In Vitro And In Vivo.
    Kang N; Zhou J; Xu J; Zhou D; Shi W
    Onco Targets Ther; 2019; 12():8915-8933. PubMed ID: 31802903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potassium voltage‑gated channel subfamily E member 4 facilitates the malignant progression of colon cancer by enhancing EGF containing fibulin extracellular matrix protein 2 expression.
    Xu Y; Wang D; Zhao G
    Exp Ther Med; 2023 Aug; 26(2):392. PubMed ID: 37456174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GALNT14 promotes lung-specific breast cancer metastasis by modulating self-renewal and interaction with the lung microenvironment.
    Song KH; Park MS; Nandu TS; Gadad S; Kim SC; Kim MY
    Nat Commun; 2016 Dec; 7():13796. PubMed ID: 27982029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GALNT14-mediated O-glycosylation on PHB2 serine-161 enhances cell growth, migration and drug resistance by activating IGF1R cascade in hepatoma cells.
    Chu YD; Fan TC; Lai MW; Yeh CT
    Cell Death Dis; 2022 Nov; 13(11):956. PubMed ID: 36376274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mucin-type glycosylating enzyme polypeptide N-acetylgalactosaminyltransferase 14 promotes the migration of ovarian cancer by modifying mucin 13.
    Wang R; Yu C; Zhao D; Wu M; Yang Z
    Oncol Rep; 2013 Aug; 30(2):667-76. PubMed ID: 23708057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EFEMP2 promotes colon cancer cell invasion and growth through the ERK1/2 signaling pathway.
    Zhao J; Xu J; Zhao J; Zhang R
    Int J Clin Exp Pathol; 2019; 12(3):851-856. PubMed ID: 31933893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of GALNT14 in lung metastasis of breast cancer.
    Kim MY
    BMB Rep; 2017 May; 50(5):233-234. PubMed ID: 28347399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polypeptide N-Acetylgalactosaminyltransferase 14 (GALNT14) as a Chemosensitivity-Related Biomarker for Osteosarcoma.
    Xi Q; Ma J
    J Oncol; 2023; 2023():1083423. PubMed ID: 38024474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab.
    Stern HM; Padilla M; Wagner K; Amler L; Ashkenazi A
    Clin Cancer Res; 2010 Mar; 16(5):1587-96. PubMed ID: 20179215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GALNT14: An Emerging Marker Capable of Predicting Therapeutic Outcomes in Multiple Cancers.
    Lin WR; Yeh CT
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32098271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Stratification of Advanced Gastric Signet Ring Cell Carcinoma by Clinicopathological Factors and
    Chen TH; Lin WR; Lee C; Chiu CT; Hsu JT; Yeh TS; Lin KH; Le PH; Yeh CT
    J Cancer; 2018; 9(19):3540-3547. PubMed ID: 30310511
    [No Abstract]   [Full Text] [Related]  

  • 17. GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization.
    Liang KH; Lin CL; Chen SF; Chiu CW; Yang PC; Chang ML; Lin CC; Sung KF; Yeh C; Hung CF; Chien RN; Yeh CT
    Pharmacogenomics; 2016 Mar; 17(4):353-66. PubMed ID: 26871639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oridonin enhances TRAIL-induced apoptosis through GALNT14-mediated DR5 glycosylation.
    Jeon MY; Seo SU; Woo SM; Min KJ; Byun HS; Hur GM; Kang SC; Kwon TK
    Biochimie; 2019 Oct; 165():108-114. PubMed ID: 31336136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.
    Lin WR; Chiang JM; Liang KH; Lim SN; Lai MW; Tsou YK; Hsieh TY; Hsu CK; Yeh CT
    Medicine (Baltimore); 2016 Apr; 95(17):e3487. PubMed ID: 27124048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.
    Wu YM; Liu CH; Hu RH; Huang MJ; Lee JJ; Chen CH; Huang J; Lai HS; Lee PH; Hsu WM; Huang HC; Huang MC
    Cancer Res; 2011 Dec; 71(23):7270-9. PubMed ID: 21990321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.